Orthocell (OCC) investor relations material

Executive summary

• Q1 FY27 revenue was A$3.6M, up 19% YoY and down 7% QoQ; Remplir revenue grew 20% QoQ and exceeded 40% of quarterly revenue.

• U.S. Remplir unit sales rose 25% to 149; commercial access expanded to seven countries, with sales launched in Thailand.

Financial highlights

• U.S. Remplir revenue reached A$0.40M, up 21% QoQ; global Remplir revenue reached a record.

• Total revenue declined 7% QoQ, reflecting lower non-Remplir revenue and timing of Striate+ revenue recognition; total revenue was up 19% YoY.

• Customer cash receipts were A$2.6M versus A$2.5M in June; operating cash use was A$4.5M, or A$3.9M excluding A$0.6M of non-recurring expenditure.

• Funds available at quarter-end were A$39.0M, comprising A$5.2M cash and A$33.8M in securities and term deposits.

Outlook and guidance

• Management expects significant revenue growth in coming quarters, supported by continued U.S. Remplir sales growth and anticipated recovery in non-Remplir revenue.

• Existing funds are expected to support commercialisation, operations to profitability, planned investment and R&D; no additional funding is anticipated.

• The national integrated delivery network contract takes effect in November; manufacturing investment is planned to increase annual capacity from ~100,000 units to more than 350,000.

• UK and EU clearance is expected by end-CY2026; market-access preparation continues with KOLs and distributor LEDA Orthopaedics.